drugset / Trial / NCT01266057
Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the highest tolerable dose of sirolimus or vorinostat that can be given in combination with hydroxychloroquine to patients with advanced cancer. The safety of these drug combinations will also be studied.
Timeline
- Start
- 2011-04-28
- Primary completion
- 2021-02-11
- Completion
- 2021-02-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydroxychloroquine | Small molecule | 200 mg | Oral |
| Subject | Sirolimus | Small molecule | 2 mg | Oral |
| Subject | Vorinostat | Small molecule | 200 mg | Oral |